F

Amicus Therapeutics
D

FOLD

9.67000
USD
0.19
(1.95%)
Market Closed
Volume
48,068
EPS
-0
Div Yield
-
P/E
-29
Market Cap
2,889,451,825
Related Instruments
    A
    ARWR
    -2.890
    (-13.49%)
    18.540 USD
    B
    BLUE
    -0.04270
    (-11.74%)
    0.32090 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    E
    EDIT
    -0.11500
    (-4.14%)
    2.66500 USD
    N
    NTLA
    -1.165
    (-7.71%)
    13.955 USD
    Q
    QURE
    -0.55000
    (-8.14%)
    6.21000 USD
    S
    SGMO
    -0.10000
    (-4.67%)
    2.04000 USD
    S
    SRPT
    -4.470
    (-4.10%)
    104.600 USD
    VRTX
    VRTX
    -18.53
    (-3.83%)
    450.72 USD
    More
News

Title: Amicus Therapeutics

Sector: Healthcare
Industry: Biotechnology
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.